AIM Overview

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AIM ImmunoTech Inc revenue for the last quarter amounts to 22.00K USD, increased 37.50

AIM ImmunoTech Inc. EPS for the last quarter amounts to -0.69 USD, decreased -86.91

AIM ImmunoTech Inc (AIM) has 19 emplpoyees as of May 31 2026.

Today AIM has the market capitalization of 9.80M USD.